Implantica AG

Equities

IMP A SDB

SE0014855029

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm Other stock markets 08:21:14 2024-04-25 am EDT			5-day change	1st Jan Change
27.45 ^SEK	-1.96%		-4.19%	+14.85%

Mar. 27	Implantica Submits Initial Module of US FDA Premarket Approval Application for GERD Medical Device	MT
Mar. 27	Implantica Submits U.S. FDA Premarket Approval Application for RefluxStop® (first module)	CI

Implantica AG Reports Earnings Results for the Full Year Ended December 31, 2021

February 18, 2022 at 02:00 am EST

Implantica AG reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was EUR 0.387 million compared to EUR 0.152 million a year ago. Net loss was EUR 15.36 million compared to EUR 10.28 million a year ago.

Latest news about Implantica AG

Implantica Submits Initial Module of US FDA Premarket Approval Application for GERD Medical Device	Mar. 27	MT
Implantica Submits U.S. FDA Premarket Approval Application for RefluxStop® (first module)	Mar. 27	CI
Implantica Completes Human Factors Validation Study for RefluxStop as Part of the US FDA Premarket Approval Process	Mar. 26	CI
Implantica to Deploy GERD Treatment in Spain	Mar. 19	MT
Implantica AG (publ.) Wins Another RefluxStop Public Tender in Europe with Hospital Universitario De Getafe	Mar. 19	CI
Implantica AG (OM:IMP A SDB) acquired IRCCS Saverio De Bellis.	Mar. 04	CI
Transcript : Implantica AG, Q4 2023 Earnings Call, Feb 16, 2024	Feb. 16
Implantica AG Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 16	CI
Implantica Announces Completion of its First RefluxStop Procedures at Artemed Klinikum München Süd in Munich, Germany	Feb. 15	CI
Implantica Announces First Refluxstop Public Tender Win, Paving the Way for Permanent Reimbursement in Italy	Feb. 13	CI
Implantica Ag Announces the First RefluxStop Procedures Completed At MIC Hospital in Berlin	Feb. 06	CI
Implantica AG (publ.) Adds Another RefluxStop Center in Spain	Dec. 18	CI
Transcript : Implantica AG, Q3 2023 Earnings Call, Nov 22, 2023	Nov. 22
Implantica AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Implantica AG (publ.)'s RefluxStop Offers for the First Time in the NHS in UK	Nov. 21	CI
Implantica Wins EU Medical Device Certifications	23-09-07	MT
Implantica AG Receives MDR Certification for RefluxStop?	23-09-07	CI
Transcript : Implantica AG, Q2 2023 Earnings Call, Aug 24, 2023	23-08-24
Implantica AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Implantica AG Further Expands Its Commercial Footprint in Italy	23-06-29	CI
Implantica AG Announces RefluxStop Results Were Presented At the DDW Conference in Chicago	23-05-16	CI
Transcript : Implantica AG, Q1 2023 Earnings Call, May 12, 2023	23-05-12
Tranche Update on Implantica AG (OM:IMP A SDB)'s Equity Buyback Plan announced on April 6, 2023.	23-05-12	CI
Implantica AG Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Implantica AG (OM:IMP A SDB) commences an Equity Buyback Plan, under the authorization approved on May 10, 2022.	23-04-06	CI

Chart Implantica AG

Duration

Period

More charts

Company Profile

Implantica AG is Lichtenstein-based medical technology Company, whose mission is to provide effective treatment for serious health conditions and to improve patients' life through the use of advanced technologies in the human body, ultimately aiming to reduce costs and increase efficiency in the healthcare System. The therapies developed by Implantica are based on implants that are inserted into the patient's body and remain in the body permanently or semi-permanently to replace bodily functions and/or treat diseases. The Company focuses on the discovery, development and prospective commercialization of medical products and implants that are intended for use in different treatment fields like in the area of gastrointestinal surgery and urology. The Company's lead product is RefluxStop, a passive, implant to prevent gastroesophageal reflux disease (GERD).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Implantica AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.406 EUR

Average target price

3.834 EUR

Spread / Average Target

+59.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
IMPLANTICA AG	+14.85%	728M
SHOCKWAVE MEDICAL, INC.	+72.58%	12.34B
PENUMBRA, INC.	-18.04%	7.98B
GETINGE AB	+3.61%	5.81B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+6.65%	5.04B
APT MEDICAL INC.	+20.83%	4.31B
ASAHI INTECC CO., LTD.	-20.27%	4.03B
INARI MEDICAL, INC.	-41.19%	2.21B
SKAN GROUP AG	+0.12%	1.99B
SHENZHEN YHLO BIOTECH CO., LTD.	+4.02%	1.87B

Medical Equipment